This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Dana-Farber-Cancer Institute Inc., Novartis Ag. Active years: 2017.
Company Filing History:
1 out of 1,265 
1 out of 3,974 
Years Active: 2017
Title: Junxia Min: Innovator in Breast Cancer Treatment
Introduction
Junxia Min is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of cancer research. He has developed innovative methods aimed at treating breast cancer, particularly focusing on estrogen receptor (ER) negative cases. His work has the potential to impact the lives of many patients suffering from this challenging condition.
Latest Patents
Junxia Min holds a patent for a groundbreaking method titled "MELK regulation for the treatment of breast cancer." This patent outlines methods for inhibiting the growth or proliferation of breast cancer cells by administering a MELK inhibitor. The methods are particularly effective for breast cancer cells that are estrogen receptor (ER) negative. Additionally, the patent includes methods for identifying patients who are likely to benefit from treatment with MELK inhibitors or FoxM1 inhibitors.
Career Highlights
Throughout his career, Junxia Min has worked with esteemed organizations such as the Dana-Farber Cancer Institute and Novartis AG. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant advancements in cancer treatment.
Collaborations
Junxia Min has collaborated with notable colleagues, including Xizhong Huang and Jean Zhao. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in cancer research.
Conclusion
Junxia Min's work in developing methods for treating breast cancer showcases his dedication to improving patient outcomes. His innovative approaches and collaborations with leading institutions highlight the importance of research in the fight against cancer.